Risk assessments are integral for the prevention and management of cardiometabolic disease (CMD). However, individuals may develop CMD without traditional risk factors, necessitating the development of novel biomarkers to aid risk prediction. The emergence of omic technologies, including genomics, proteomics, and metabolomics, has allowed for assessment of orthogonal measures of cardiometabolic risk, potentially improving the ability for novel biomarkers to refine disease risk assessments. While omics has shed light on novel mechanisms for the development of CMD, its adoption in clinical practice faces significant challenges. We review select omic technologies and cardiometabolic investigations for risk prediction, while highlighting challenges and opportunities for translating findings to clinical practice.

中文翻译：

---

组学和心脏代谢疾病风险预测。

风险评估对于预防和管理心脏代谢性疾病（CMD）至关重要。但是，个体可能会在没有传统危险因素的情况下发展CMD，因此有必要开发新型生物标记物以辅助风险预测。包括基因组学，蛋白质组学和代谢组学在内的眼科学技术的出现，使得人们可以评估心脏代谢风险的正交测量，从而有可能提高新型生物标志物完善疾病风险评估的能力。虽然组学组已经阐明了CMD发展的新机制，但其在临床实践中的采用面临着巨大的挑战。我们回顾了选定的眼科学技术和心脏代谢研究，以进行风险预测，同时重点介绍了将发现转化为临床实践所面临的挑战和机遇。